{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:43:24Z","timestamp":1790639004231,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","funder":[{"name":"Innovate UK via the Northern Alliance Advanced Therapies Treatment Centre","award":["RD 9791"],"award-info":[{"award-number":["RD 9791"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,9,17]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Chimeric Antigen Receptor T-cell (CAR-T) therapy is a complex, novel treatment for patients with relapsed\/refractory haematological malignancies. Despite its advancement, research on the supportive care needs of this patient group and their caregivers is limited. This study aimed to explore the experiences of patients undergoing CAR-T cell therapy and their caregivers and identify any unmet needs of this group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicentre, qualitative, longitudinal study recruited nine patients and five caregivers from three UK CAR-T therapy centres. Semistructured interviews were carried out between October 2021 and October 2022 and conducted in three phases: within 3\u2009weeks of leukapheresis, mid-treatment and within 4\u2009weeks of the first positron emission tomography scan (performed at 28 days postinfusion to assess treatment response). Thematic analysis was used to analyse interview data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thematic analysis identified five distinct themes: the rollercoaster journey to reach CAR-T; balancing hope, realism and resignation; navigating CAR-T side effects and their impact; barriers to addressing uncertainty; and the tapestry of support. Notably, a high symptom burden and unique treatment toxicities were evident, alongside the need to navigate an uncertain (yet potentially curative) disease trajectory. Support from a dedicated CAR-T nurse specialist was crucial, and the potential of further palliative\/supportive care provision was underscored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The experience of CAR-T therapy is characterised by often unique symptom burden, uncertainty and resilience. It is vitally bolstered by the support of professionals and carers. There is evidence of missed opportunities to support patients and caregivers with the challenges of navigating an uncertain future, and \u2018parallel planning\u2019 conversations may be a way to meet this need. Future research should focus on the involvement of collaborative palliative\/supportive care to support this patient group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/spcare-2025-005371","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:20:14Z","timestamp":1758907214000},"page":"spcare-2025-005371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Patient and carer experience of chimeric antigen receptor T-cell therapy: a multicentre qualitative study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3655-2010","authenticated-orcid":false,"given":"Laura","family":"Barnes","sequence":"first","affiliation":[{"name":"Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Stenson","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Vidrine","sequence":"additional","affiliation":[{"name":"Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8189-2746","authenticated-orcid":false,"given":"Rachel","family":"Stocker","sequence":"additional","affiliation":[{"name":"School of Biomedical, Nutritional and Sport Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2025100101500657000_spcare-2025-005371v2.1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176091","article-title":"Drug Resistance in Hematological Malignancies","volume":"21","author":"Auberger","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100101500657000_spcare-2025-005371v2.2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7150\/jca.48976","article-title":"Current Progress in CAR-T Cell Therapy for Hematological Malignancies","volume":"12","author":"Han","year":"2021","journal-title":"J Cancer"},{"key":"2025100101500657000_spcare-2025-005371v2.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100101500657000_spcare-2025-005371v2.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"2025100101500657000_spcare-2025-005371v2.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100101500657000_spcare-2025-005371v2.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"2025100101500657000_spcare-2025-005371v2.7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100101500657000_spcare-2025-005371v2.8","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2018.20","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u201cALL\u201d","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100101500657000_spcare-2025-005371v2.9","article-title":"Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"130","author":"Schuster","year":"2017","journal-title":"Blood"},{"key":"2025100101500657000_spcare-2025-005371v2.10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2025100101500657000_spcare-2025-005371v2.11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long-term survivorship care after CAR-T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"key":"2025100101500657000_spcare-2025-005371v2.12","unstructured":"National Institute for Health and Care Excellence (NICE) . Axicabtagene ciloleucel for treating relapsed or refractory diffuse large b-cell lymphoma after first-line chemoimmunotherapy (TA895). 2023. Available: www.nice.org.uk\/guidance\/ta895\/chapter\/1-Recommendation [Accessed 08 Oct 2024]."},{"key":"2025100101500657000_spcare-2025-005371v2.13","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000802","article-title":"Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review","volume":"6","author":"Efficace","year":"2022","journal-title":"Hemasphere"},{"key":"2025100101500657000_spcare-2025-005371v2.14","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgm005"},{"key":"2025100101500657000_spcare-2025-005371v2.15","doi-asserted-by":"crossref","first-page":"151216","DOI":"10.1016\/j.soncn.2021.151216","article-title":"The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy","volume":"37","author":"Whisenant","year":"2021","journal-title":"Semin Oncol Nurs"},{"key":"2025100101500657000_spcare-2025-005371v2.16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"key":"2025100101500657000_spcare-2025-005371v2.17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1177\/0269216320954621","article-title":"Hoping for the best and preparing for the worst: a forgotten maxim in the immunotherapy era?","volume":"34","author":"LeBlanc","year":"2020","journal-title":"Palliat Med"},{"key":"2025100101500657000_spcare-2025-005371v2.18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/02692163221138880","article-title":"A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams","volume":"37","author":"Stenson","year":"2023","journal-title":"Palliat Med"},{"key":"2025100101500657000_spcare-2025-005371v2.19","first-page":"254","article-title":"Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T","volume":"29","author":"Akinola","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025100101500657000_spcare-2025-005371v2.20","doi-asserted-by":"publisher","DOI":"10.1007\/s11135-017-0574-8"},{"key":"2025100101500657000_spcare-2025-005371v2.21","doi-asserted-by":"publisher","DOI":"10.1080\/17439760.2016.1262613"},{"key":"2025100101500657000_spcare-2025-005371v2.22","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"key":"2025100101500657000_spcare-2025-005371v2.23","first-page":"452","article-title":"Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Barata","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100101500657000_spcare-2025-005371v2.24","doi-asserted-by":"crossref","first-page":"100692","DOI":"10.1016\/j.blre.2020.100692","article-title":"Illness and prognostic understanding in patients with hematologic malignancies","volume":"45","author":"Gray","year":"2021","journal-title":"Blood Rev"},{"key":"2025100101500657000_spcare-2025-005371v2.25","doi-asserted-by":"crossref","first-page":"8052","DOI":"10.1182\/blood-2022-159737","article-title":"Developing and Implementing an Advance Care Planning Service for Patients with Haematological Malignancies Preparing to Undergo CAR-T Therapy","volume":"140","author":"Tate","year":"2022","journal-title":"Blood"},{"key":"2025100101500657000_spcare-2025-005371v2.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5161"},{"key":"2025100101500657000_spcare-2025-005371v2.27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jpainsymman.2021.03.014","article-title":"Outcomes of Specialty Palliative Care Interventions for Patients With Hematologic Malignancies: A Systematic Review","volume":"62","author":"Elliott","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2025100101500657000_spcare-2025-005371v2.28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamainternmed.2015.6599","article-title":"Timeliness of End-of-Life Discussions for Blood Cancers: A National Survey of Hematologic Oncologists","volume":"176","author":"Odejide","year":"2016","journal-title":"JAMA Intern Med"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T08:50:19Z","timestamp":1759308619000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":28,"alternative-id":["10.1136\/spcare-2025-005371"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005371","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}